Talon battered by 3-month US FDA delay for Marqibo
This article was originally published in Scrip
Talon Therapeutics' investors panicked on 7 May after the firm disclosed the US FDA delayed its decision by three months on the San Mateo, California-based company's new drug application for Marqibo (vincristine sulfate liposomes injection) as a treatment for adults with Philadelphia chromosome negative (Ph-) acute lymphoblastic leukaemia (ALL) in second or greater relapse or whose disease has progressed following two or more treatment lines of antileukaemia therapy – with shares plummeting as low as 40%.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.